However, the role of the AKT/mTOR/STAT3/ID1 axis in liver cancer remains unexplored, and the effects of therapeutics targeting the AKT/mTOR/STAT3/ID1 signaling pathway remain unknown. This evidence concerns the gene MTOR and liver cancer.